magnesium supplement (OTC)

Brand and Other Names:Mag-Tab SR

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

caplet

  • 84mg

Magnesium Deficiency

168-336 mg PO divided BID

Renal Insufficiency

CrCl<30 mL/min: Use caution; monitor for hypermagnesemia

CrCl≥30 mL/min: Dose adjustement not necessary

Safety & efficacy not established

Next:

Interactions

Interaction Checker

and magnesium supplement

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (2)

            • baloxavir marboxil

              magnesium supplement will decrease the level or effect of baloxavir marboxil by Other (see comment). Contraindicated. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms

            • raltegravir

              magnesium supplement will decrease the level or effect of raltegravir by Other (see comment). Contraindicated. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms

            Serious - Use Alternative (0)

              Monitor Closely (50)

              • alendronate

                magnesium supplement will decrease the level or effect of alendronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

              • amikacin

                magnesium supplement, amikacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • amlodipine

                magnesium supplement, amlodipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

              • atracurium

                magnesium supplement, atracurium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • bictegravir

                magnesium supplement will decrease the level or effect of bictegravir by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 6 hr after

              • calcitriol

                magnesium supplement will increase the level or effect of calcitriol by Other (see comment). Modify Therapy/Monitor Closely. Drug may increase absorption of magnesium in the intestine and colon, which increases risk of hypermagnesemia

              • ciprofloxacin

                magnesium supplement will decrease the level or effect of ciprofloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 6hr after the quinolone

              • cisatracurium

                magnesium supplement, cisatracurium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • clevidipine

                magnesium supplement, clevidipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

              • deferiprone

                magnesium supplement will decrease the level or effect of deferiprone by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 4 hr from polyvalent cation administration

              • delafloxacin

                magnesium supplement will decrease the level or effect of delafloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 6hr after the quinolone

              • demeclocycline

                magnesium supplement will decrease the level or effect of demeclocycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

              • diltiazem

                magnesium supplement, diltiazem. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

              • dolutegravir

                magnesium supplement will decrease the level or effect of dolutegravir by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 6 hr after

              • doxercalciferol

                magnesium supplement will increase the level or effect of doxercalciferol by Other (see comment). Modify Therapy/Monitor Closely. Drug may increase absorption of magnesium in the intestine and colon, which increases risk of hypermagnesemia

              • doxycycline

                magnesium supplement will decrease the level or effect of doxycycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

              • eltrombopag

                magnesium supplement will decrease the level or effect of eltrombopag by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 4 hr after

              • etidronate

                magnesium supplement will decrease the level or effect of etidronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

              • felodipine

                magnesium supplement, felodipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

              • gabapentin

                magnesium supplement will decrease the level or effect of gabapentin by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 2 hr from polyvalent cation administration

              • gemifloxacin

                magnesium supplement will decrease the level or effect of gemifloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 3hr after the quinolone

              • gentamicin

                magnesium supplement, gentamicin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • ibandronate

                magnesium supplement will decrease the level or effect of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

              • isradipine

                magnesium supplement, isradipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

              • levofloxacin

                magnesium supplement will decrease the level or effect of levofloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 2hr after the quinolone

              • levothyroxine

                magnesium supplement will decrease the level or effect of levothyroxine by Other (see comment). Modify Therapy/Monitor Closely. Drug may adsorb to magnesium; may decrease absorption by the intestinal tract; applies to oral forms; may separate administration of drugs by 4 hr

              • minocycline

                magnesium supplement will decrease the level or effect of minocycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

              • moxifloxacin

                magnesium supplement will decrease the level or effect of moxifloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 4hr before the quinolone or 8hr after the quinolone

              • mycophenolate

                magnesium supplement will decrease the level or effect of mycophenolate by Other (see comment). Modify Therapy/Monitor Closely. Drug may bind to magnesium ions in the GI tract, which decreases absorption; separate administration of drugs to minimize interaction

              • neomycin PO

                magnesium supplement, neomycin PO. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • nicardipine

                magnesium supplement, nicardipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

              • nifedipine

                magnesium supplement, nifedipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

              • nimodipine

                magnesium supplement, nimodipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

              • nisoldipine

                magnesium supplement, nisoldipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

              • omadacycline

                magnesium supplement will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline..

                magnesium supplement will decrease the level or effect of omadacycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

              • pancuronium

                magnesium supplement, pancuronium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • penicillamine

                magnesium supplement will decrease the level or effect of penicillamine by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 1 hr from polyvalent cation administration

              • plazomicin

                magnesium supplement, plazomicin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • potassium phosphate

                magnesium supplement will decrease the level or effect of potassium phosphate by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with divalent cations; may decrease absorption by the intestinal tract; applies to oral forms; separate administration of drugs to avoid interaction

              • risedronate

                magnesium supplement will decrease the level or effect of risedronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

              • rocuronium

                magnesium supplement, rocuronium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • sarecycline

                magnesium supplement will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline..

                magnesium supplement will decrease the level or effect of sarecycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

              • streptomycin

                magnesium supplement, streptomycin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • succinylcholine

                magnesium supplement, succinylcholine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • tetracycline

                magnesium supplement will decrease the level or effect of tetracycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline

              • tiludronate

                magnesium supplement will decrease the level or effect of tiludronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

              • tobramycin

                magnesium supplement, tobramycin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • trientine

                magnesium supplement will decrease the level or effect of trientine by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 1hr before the trietine or 1hr after the trientine

              • vecuronium

                magnesium supplement, vecuronium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

              • verapamil

                magnesium supplement, verapamil. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

              Minor (0)

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                Diarrhea

                Previous
                Next:

                Warnings

                Contraindications

                Hypersensitivity

                Cautions

                Use with caution in patients with neuromuscular disease, including myasthenia gravis

                Diets high in fat may cause decreased magnesium absorption

                Monitor patients with severe renal impairment for magnesium toxicity; use caution

                When used for self-medication, not for long term use; not for use if nausea, vomiting, or abdominal pain present; patients with impaired kidney function should use under the supervision of healthcare professional

                When taking dietary supplements, it is especially important that patient inform healthcare professional as supplements may interfere with activity of prescription medications

                Magnesium supplements may worsen cardiac conditions

                Contact healthcare professional if after taking the supplement experience flushing, dizziness or fainting, muscle paralysis, trouble breathing

                Symptoms of overdose especially in patients with impaired kidney function may include drowsiness, slow heartbeat, trouble breathing, dizziness or fainting, blurred or double vision, coma

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy

                Not studied; magnesium crosses the placenta; effects of supplementation on neonate unknown

                Healthy growth and development of fetus depend on a steady supply of nutrients from the mother; however, taking large amounts of dietary supplements during pregnancy may be harmful to the mother and/or fetus and should be avoided

                Lactation

                Magnesium is present in breast milk; supplementation generally considered cmpatible with breastfeeding; however, taking large amounts of a dietary supplement while breast-feeding may be harmful to the mother and/or baby and should be avoided

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Magnesium plays a role as a cofactor of various enzymatic activities, including metabolic reactions and protein synthesis. It also plays a role lipoprotein lipase activity, which is involved in cholesterol metabolism. .

                Previous
                Next:

                Administration

                Oral Administration

                Administer with food

                Extended-release form

                • Swallow the tablets whole; do not chew or suck on the tablet
                • Some tablets may be broken or crushed and sprinkled on applesauce or other soft food; check with healthcare professional first, since this should not be done for most extended-release tablets
                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.